---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-255479"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-06-03T20:16:49+00:00"
generated_at: "2026-06-03T20:48:18.261943+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma stockholders approve 2026 stock plan and warrant issuance

## Summary
- Warrant share issuance from May 2026 licensing transaction approved (1.78M For, 113K Against).
- 2026 Stock Incentive Plan approved with 1.26M For, 632K Against, 2,687 Abstain.
- Adjournment proposal approved (1.30M For, 582K Against); not needed as main proposals passed.

## SEC filing metadata
- accession: 0001193125-26-255479
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-06-03T20:16:49+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/0001193125-26-255479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/cue-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-255479
- JSON: https://secwatch.observer/filing/0001193125-26-255479.json
- Plain text: https://secwatch.observer/filing/0001193125-26-255479.txt

## Key facts
- Shareholder Votes
  Cue Biopharma, Inc. shareholders approved Issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement.
  - Outcome: passed
  source text: The Company’s stockholders approved, in accordance with Nasdaq Listing Rule 5635(a), (c) and (d), the issuance of shares of common stock upon the exercise of certain warrants issued by the Company in May 2026 in connection with a licensing transaction and related private placement (“Proposal 1”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,782,133 113,311 1,013 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/0001193125-26-255479-index.htm
- Shareholder Votes
  Cue Biopharma, Inc. shareholders approved Adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2.
  - Outcome: passed
  source text: The Company’s stockholders approved the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 1 and/or Proposal 2 (“Proposal 3”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,302,751 582,084 11,622 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/0001193125-26-255479-index.htm
- Shareholder Votes
  Cue Biopharma, Inc. shareholders approved 2026 Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: The Company’s stockholders approved the 2026 Plan (“Proposal 2”), with votes cast as follows: For Against Abstain Broker Non-Votes 1,261,296 632,474 2,687 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/0001193125-26-255479-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.